Drug intelligence / Profile preview

ribavirin elaidate

Development stage: Preclinical
Lead developer: Translational Therapeutics
Modality: Small Molecules

Overview

Ribavirin elaidate is a lipid vector technology derivative of ribavirin. It is an investigational small molecule drug developed for the treatment of aggressive thyroid cancers (follicular, medullary, anaplastic thyroid carcinoma). The compound acts as a prodrug of ribavirin and is designed to inhibit eukaryotic initiation factor 4E (elF4E), which plays a role in cell growth and cancer progression. It has received orphan drug status from the FDA for these indications but has not progressed beyond preclinical development.[3][4][7]

Other names: Ribavirin-5'-elaidic acid ester1h-1,2,4-triazole-3-carboxamide, 1-(5-o-((9e)-1-oxo-9-octadecen-1-yl)-.beta.-d-ribofuranosyl)-[1]

Targets

EIF4E (Eukaryotic translation initiation factor 4E)

Beyond the preview

Go deeper on ribavirin elaidate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ribavirin elaidate.

Explore the full profile